[CLAIMS]

1. Use of tiotropium, or a salt thereof or a hydrate thereof, in the manufacture of a medicament for the prevention of myopia, treatment of myopia, and/or prevention of myopia progression.

2. The use of claim 1, characterized in that the medicament does not substantially have mydriatic action.

3. The use of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate thereof in the medicament is about 0.000001 to about 5 % (w/v).

4. The use of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate thereof in the medicament is about 0.00001 to about 2 % (w/v).

5. The use of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate thereof in the medicament is about 0.0001 to about 2 % (w/v).

6. The use of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate thereof in the medicament is about 0.0001 to about 1 % (w/v).

7. The use of claim 1 or 2, wherein the concentration of

tiotropium or a salt thereof or a hydrate thereof in the medicament is about 0.0001 to about 0.1 % (w/v).

8. The use of claim 1 or 2, wherein the concentration of tiotropium or a salt thereof or a hydrate thereof in the medicament is about 0.0001 to about 0.01 % (w/v).

9. The use of any one of claims 1 to 8, wherein the medicament is for ocular topical administration.

10. The use of claim 9, wherein the ocular topical administration is instillation administration or intravitreal administration.

11. The use of any one of claims 1 to 10, wherein the medicament is formulated as an eyedrop, eye gel, ophthalmic ointment or injection.

12. The use of any one of claims 1 to 11, wherein the tiotropium or a salt thereof or a hydrate thereof is tiotropium bromide hydrate.

13. Use of tiotropium, or a salt thereof or a hydrate thereof, in the manufacture of a medicament for suppressing the axial length elongation.